Lyron L Bentovim bought $7,942 of LOAN
director at MANHATTAN BRIDGE CAPITAL, INC. 1,757 shares at an average of $4.52, traded Nov 19, 2025, filed Nov 19, 2025.
Score components
- +15RoleDirector
- 0Trade size$8k at market
- 0Relative to holdingsHoldings up 4.5%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +13.5%, 3m +3.7%, 6m +1.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-25-024248, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | POpen-market purchase Common Stock | +1,757 | $4.52 | $7,942 | 41,044 | Nov 19, 2025 |
Related signals
Other insiders at MANHATTAN BRIDGE CAPITAL, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | LOANbuy MANHATTAN BRIDGE CAPITAL, INC | Assaf Ran President and CEO | $32k 8,000 shares | +1% | |
| 28Weak | MANHATTAN BRIDGE CAPITAL, INC | Assaf Ran President and CEO | $19k 4,000 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.